Robot-Assisted Surgery: A Promising Tool Yet to Prove Superiority

By Staff Writer

September 7, 2023

Robot-Assisted Surgery (RAS) is a technologically advanced form of minimally invasive surgery, offering a higher degree of precision compared to traditional laparoscopic methods. RAS allows surgeons to control the instruments of the robotic system remotely, providing a further minimally invasive surgical option for patients.

According to the World Health Organization (WHO), there are currently 19 known manufacturers of robotic systems designed to aid in surgical procedures. The most widely used among these is the da Vinci® Surgical System.

The Austrian Institute for Health Technology Assessment (AIHTA) report focused on the use of RAS in thoracic and visceral surgery. Thoracic surgery primarily treats conditions of the lungs, chest wall, and diaphragm, while visceral surgery focuses on diseases of abdominal organs, the gastrointestinal tract, endocrine organs, the abdominal wall, and the peritoneum.
However, the report revealed mixed results regarding the effectiveness and safety of RAS. While RAS claims to reduce readmissions and shorten hospital stays, no statistically significant differences were detected compared to laparoscopic or open procedures.

On the positive side, RAS resulted in decreased blood loss in certain procedures and fewer postoperative complications in others. However, it also tends to have a higher mean cost per procedure than conventional surgical methods.

The report concluded that while RAS might present potential advantages for certain indications and outcomes, most of the claimed benefits could not be materialised. Moreover, the financial and environmental implications must be considered in purchasing decisions.

In conclusion, while RAS is a promising tool in the field of surgery, more comprehensive studies with larger sample sizes and longer follow-up times are needed to conclusively determine its superiority over traditional surgical methods.

Reference url

Recent Posts

Zimislecel type 1 diabetes
   

Cell Therapy for Type 1 Diabetes: Vertex Trial Results and Market Potential

🚀 What if we could revolutionize Type 1 diabetes treatment?

Vertex Pharmaceuticals has made significant strides with its promising phase 1/2 trial results for **zimislecel**, a stem cell-derived therapy that not only restores insulin production but also drastically reduces severe hypoglycemic events. As phase 3 trials commence, this breakthrough could reshape care for T1D patients and potentially reduce long-term healthcare costs.

Curious to learn how zimislecel and other potential cell therapies may redefine diabetes management? Click to read more!

#SyenzaNews #biotechnology #HealthEconomics

biosimilar clinical approach
    

Biosimilar Clinical Approach

🚀 How is the EMA’s new biosimilar clinical approach changing the landscape of drug approvals in Europe?

With a focus on tailored clinical assessments, the EMA is streamlining the pathway for biosimilars by allowing analytical data to take precedence over large-scale comparative efficacy studies. This shift promises to enhance patient access to life-saving therapies while maintaining rigorous safety standards.

Dive deeper into the implications of this innovative regulatory approach and find out how it can impact health economics and market access.

👉 Read more in the full article!
#SyenzaNews #regulatoryaffairs #MarketAccess

HIV prevention injection
   

FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Prevention

🌍 Will Yeztugo Approval and Access Strategy Deliver an Inflection Point in HIV/AIDS?

Yeztugo (lenacapavir), a twice-yearly injection, redefines long-acting HIV prevention with 96–100% efficacy. Gilead’s access strategy—insurance, assistance, and generics for 120 countries—targets global impact. Can it balance $28,218 U.S. costs with equity for 1.3M annual infections? My article explores health economics, public health, and market dynamics.

📖 Read how Yeztugo’s access strategy could transform long-acting HIV prevention

#SyenzaNews #GlobalHealth #HIVPrevention #Yeztugo #PrEP

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.